SNCE logo

Science 37 Holdings (SNCE) Stock

Profile

Full Name:

Science 37 Holdings, Inc.

Sector:

Healthcare

Industry:

Health Information Services

Country:

United States

IPO:

23 November 2020

Indexes:

Not included

Website:

http://www.science37.com

Description:

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina. As of March 11, 2024, Science 37 Holdings, Inc. operates as a subsidiary of eMed, LLC.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$70.15 M(+17.70% YoY)

Annual EPS

-$8.80(+84.78% YoY)

PE Ratio

-

Annual ROE

-46.57%

Annual Debt To Equity

0.00

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

May 15, 2024

Recent annual earnings:

Mar 06, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 08, 2023

Analyst ratings

Recent major analysts updates

07 Mar '23 Baird
Outperform
14 Nov '22 William Blair
Market Perform
14 Nov '22 Cowen & Co.
Outperform
07 June '22 Craig-Hallum
Buy
01 Nov '21 William Blair
Outperform
01 Nov '21 Lake Street
Buy
01 Nov '21 Baird
Outperform
22 Oct '21 Cowen & Co.
Outperform

Screeners with SNCE included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$282.00
SNCE price is currently at an all-time high

Price Analysts Target

$5.75
SNCE price is currently equal to the consensus analysts' forecast

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue Estimate

$58.32 M
SNCE annual revenue is currently +20.28% higher than the consensus analysts' forecast

Annual EPS Estimate

-$5.62
SNCE annual earnings per share is currently +56.58% higher than the consensus analysts' forecast

Annual Gross Profit

$15.87 M
SNCE annual gross profit is $15.87 million

Annual Operating Profit

-$105.33 M
SNCE annual operaing income is -$105.33 million

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-46.57%
SNCE annual return on equity is -46.57%

Annual ROA

-26.33%
SNCE annual return on assets is -26.33%

Annual EBIT

-$105.33 M
SNCE annual earnings before interest & taxes is -$105.33 million

Annual EBITDA

-$87.39 M
SNCE annual earnings before interest, taxes, depreciation & amortization is -$87.39 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Current Ratio

5.45
SNCE annual current ratio is 5.45

Annual Total Assets

$126.45 M
SNCE annual total assets is $126.45 million

Annual Current Assets

$126.20 M
SNCE annual total current assets is $126.20 million

Annual Total Liabilities

$29.06 M
SNCE annual total liabilities is $29.06 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CAPEX

$31.87 M
SNCE annual capital expenditures is $31.87 million

Annual FCF

-$107.32 M
SNCE annual free cash flow is -$107.32 million

Institutional Ownership

Similar stocks

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
SNCE
globenewswire.com27 June 2024

RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets.

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
SNCE
globenewswire.com12 June 2024

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Science 37, Inc., please note that the first sentence of the second paragraph has been revised.

Science 37 Holdings, Inc. (SNCE) Q3 2023 Earnings Call Transcript
Science 37 Holdings, Inc. (SNCE) Q3 2023 Earnings Call Transcript
Science 37 Holdings, Inc. (SNCE) Q3 2023 Earnings Call Transcript
SNCE
Seeking Alpha12 November 2023

Science 37 Holdings, Inc. (NASDAQ:SNCE ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Steve Halper - Investor Relations David Coman - Chief Executive Officer Mike Zaranek - Chief Financial Officer Conference Call Participants Charles Rhyee - Cowen and Company Matt Hewitt - Craig-Hallum Christine Rains - William Blair Nelson Cox - Lake Street Operator Greetings and welcome to the Science 37 Third Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023
Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023
Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023
SNCE
GlobeNewsWire24 October 2023

RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023.

Science 37 Holdings, Inc. (SNCE) Q2 2023 Earnings Call Transcript
Science 37 Holdings, Inc. (SNCE) Q2 2023 Earnings Call Transcript
Science 37 Holdings, Inc. (SNCE) Q2 2023 Earnings Call Transcript
SNCE
Seeking Alpha12 August 2023

Science 37 Holdings, Inc. (NASDAQ:SNCE ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Steven Halper - LifeSci Advisors David Coman - CEO Mike Zaranek - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Christine Rains - William Blair Matt Hewitt - Craig-Hallum Capital Group Operator Greetings, and welcome to the Science 37 Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

FAQ

  • What is the primary business of Science 37 Holdings?
  • What is the ticker symbol for Science 37 Holdings?
  • Does Science 37 Holdings pay dividends?
  • What sector is Science 37 Holdings in?
  • What industry is Science 37 Holdings in?
  • What country is Science 37 Holdings based in?
  • When did Science 37 Holdings go public?
  • Is Science 37 Holdings in the S&P 500?
  • Is Science 37 Holdings in the NASDAQ 100?
  • Is Science 37 Holdings in the Dow Jones?
  • When was Science 37 Holdings's last earnings report?
  • When does Science 37 Holdings report earnings?
  • Should I buy Science 37 Holdings stock now?

What is the primary business of Science 37 Holdings?

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina. As of March 11, 2024, Science 37 Holdings, Inc. operates as a subsidiary of eMed, LLC.

What is the ticker symbol for Science 37 Holdings?

The ticker symbol for Science 37 Holdings is NASDAQ:SNCE

Does Science 37 Holdings pay dividends?

No, Science 37 Holdings does not pay dividends

What sector is Science 37 Holdings in?

Science 37 Holdings is in the Healthcare sector

What industry is Science 37 Holdings in?

Science 37 Holdings is in the Health Information Services industry

What country is Science 37 Holdings based in?

Science 37 Holdings is headquartered in United States

When did Science 37 Holdings go public?

Science 37 Holdings's initial public offering (IPO) was on 23 November 2020

Is Science 37 Holdings in the S&P 500?

No, Science 37 Holdings is not included in the S&P 500 index

Is Science 37 Holdings in the NASDAQ 100?

No, Science 37 Holdings is not included in the NASDAQ 100 index

Is Science 37 Holdings in the Dow Jones?

No, Science 37 Holdings is not included in the Dow Jones index

When was Science 37 Holdings's last earnings report?

Science 37 Holdings's most recent earnings report was on 15 May 2024

When does Science 37 Holdings report earnings?

The date for Science 37 Holdings's next earnings report has not been announced yet

Should I buy Science 37 Holdings stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions